CytoDyn Inc. (OTCMKTS:CYDY) Sees Significant Growth in Short Interest

CytoDyn Inc. (OTCMKTS:CYDY) saw a significant growth in short interest in December. As of December 31st, there was short interest totalling 20,123,400 shares, a growth of 15.0% from the December 15th total of 17,499,100 shares. Based on an average daily trading volume, of 6,176,200 shares, the short-interest ratio is presently 3.3 days.

CytoDyn Price Performance

OTCMKTS CYDY traded up $0.00 during trading hours on Friday, reaching $0.15. The company’s stock had a trading volume of 1,217,001 shares, compared to its average volume of 2,325,929. The firm has a fifty day simple moving average of $0.12 and a 200-day simple moving average of $0.14. CytoDyn has a 52 week low of $0.10 and a 52 week high of $0.32. The stock has a market cap of $185.14 million, a P/E ratio of -7.54 and a beta of -0.10.

CytoDyn (OTCMKTS:CYDY) last announced its earnings results on Tuesday, October 15th. The biotechnology company reported $0.02 EPS for the quarter.

About CytoDyn

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.